AIM: To observe the clinical efficacy of olopatadine eye drops combined with autologous serum in the treatment of artemisia pollen allergic conjunctivitis.

METHODS:Totally 305 patients with 610 eyes with allergic conjunctivitis and positive allergen test results of artemisia in our hospital were selected from June 2016 to June 2018, and randomly divided into the control group and the observation group. Patients in the control group were treated with olopatadine eye drops. Patients in the observation group were treated with autologous serum on the basis of the control group. Patients in both groups were treated continuously for 2wk. The total scores of symptoms and signs and clinical efficacy of the two groups were compared before and 2wk after treatment, and the adverse reactions during the treatment were observed.

RESULTS: Before treatment, there was no statistically significant difference in the total score of symptoms and signs between the two groups(P>0.05). Two weeks after treatment, the total score of symptoms and signs in the observation group was lower than that in the control group(P<0.05), and the clinical efficacy of the observation group was better than that of the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).

CONCLUSION: Olopatadine eye drops combined with autologous serum in the treatment of artemisia pollen allergic conjunctivitis has a definite clinical effect, which can effectively relieve the clinical symptoms and signs of patients with high security.